Skip to main
BDX

BDX Stock Forecast & Price Target

BDX Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 15%
Hold 54%
Sell 0%
Strong Sell 0%

Bulls say

Becton Dickinson is expected to see EPS growth through FY2030 thanks to their strong performance, new product launches, and the acquisition of Waters Corporation, while also planning to return cash to shareholders through repurchases and a $4 billion cash distribution. Despite potential risks and challenges, the company's continued focus on high-growth MedTech markets and their BD Excellence initiative bode well for their future success and drive in their stock price.

Bears say

Becton Dickinson is facing several key risks and headwinds in the near future, including the potential failure to achieve its milestones related to the separation of its Biosciences and Diagnostics divisions, ongoing headwinds and pressures in China, competition from larger and more specialized firms, potential changes in healthcare delivery and reimbursement, and potential global economic conditions that could negatively impact operations. Additionally, the company's financial performance in recent years has been affected by declines in certain segments and markets, such as Life Sciences and China, which could continue to be a drag on future growth.

BDX has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 15% recommend Buy, 54% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Becton, Dickinson and Co. (BDX) Forecast

Analysts have given BDX a Buy based on their latest research and market trends.

According to 13 analysts, BDX has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $184.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $184.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Becton, Dickinson and Co. (BDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.